|
|
非小细胞肺癌免疫治疗进展
|
Abstract:
在世界范围内，肺癌是癌症相关死亡的最常见原因。在肺癌的常见类型中，非小细胞肺癌(Non-Small Cell Lung Cancer, NSCLC)占到了所有肺癌类型的85%，手术是其早期病变的主要治疗手段，但是单纯手术治疗后局部复发及转移复发率极高。不能手术切除的非小细胞肺癌曾经一般使用化学治疗、放射治疗等方案，但是收获的效果有限。在过去的20年里，非小细胞肺癌(NSCLC)的分子靶向治疗和免疫治疗显著地改善了疗效，特别是免疫治疗在非小细胞肺癌的治疗中已经成为标准治疗方法之一。本文就目前关于非小细胞肺癌免疫治疗进展作一综述。
Lung cancer stands as the leading cause of cancer-related mortality all over the word. Non-Small Cell Lung Cancer (NSCLC), among the common lung cancer types, constitutes 85% of all cases. While surgery remains the primary treatment for early-stage lesions, the post-surgical rates of local re-currence and metastasis are notably high. Chemotherapy and radiotherapy are conventional ap-proaches for unresectable NSCLC; however, their efficacy is often limited. Over the past two decades, molecular targeted therapy and immunotherapy have markedly enhanced the outcomes for NSCLC. Notably, immunotherapy has emerged as a standard treatment modality for NSCLC. This paper re-views the advancements in immunotherapy for non-small cell lung cancer.
| [1] | Wang, M., Herbst, R.S. and Boshoff, C. (2021) Toward Personalized Treatment Approaches for Non-Small-Cell Lung Cancer. Nature Medicine, 27, 1345-1356. https://doi.org/10.1038/s41591-021-01450-2 |
| [2] | Duma, N., Santa-na-Davila, R. and Molina, J.R. (2019) Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treat-ment. Mayo Clinic Proceedings, 94, 1623-1640. https://doi.org/10.1016/j.mayocp.2019.01.013 |
| [3] | Bray, F., Fer-lay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A. and Jemal, A. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424. https://doi.org/10.3322/caac.21492 |
| [4] | Suda, K., Sato, K., Mizuuchi, H., Kobayashi, Y., Shimoji, M., Tomizawa, K., Takemoto, T., Iwasaki, T., Sakaguchi, M. and Mitsudomi, T. (2014) Recent Evidence, Advances, and Current Practices in Surgical Treatment of Lung Cancer. Respiratory Investigation, 52, 322-329. https://doi.org/10.1016/j.resinv.2014.06.003 |
| [5] | 韩莎莎, 等. 转移性非小细胞肺癌系统治疗[J]. 西北国防医学杂志, 2021, 42(5): 407-412. |
| [6] | 郭超, 张家齐, 李单青. 非小细胞肺癌新辅助免疫治疗进展[J]. 中国肺癌杂志, 2022, 25(7): 524-533. |
| [7] | Nagano, T., Tachihara, M. and Nishimura, Y. (2019) Molecular Mechanisms and Tar-geted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer. Current Cancer Drug Targets, 19, 595-630.
https://doi.org/10.2174/1568009619666181210114559 |
| [8] | Larkin, J., Minor, D., D’Angelo, S., Neyns, B., et al. (2018) Overall Survival in Patients with Advanced Melanoma Who Received Nivolumab versus Investigator’s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. Journal of Clinical Oncology, 36, 383-390. https://doi.org/10.1200/JCO.2016.71.8023 |
| [9] | Rittmeyer, A., Barlesi, F., Waterkamp, D., Park, K., et al. (2017) Atezolizumab versus Docetaxel in Patients with Previously Treated Non-Small-Cell Lung Cancer (OAK): A Phase 3, Open-Label, Multicentre Randomised Controlled Trial. The Lancet, 389, 255-265. https://doi.org/10.1016/S0140-6736(16)32517-X |
| [10] | Brahmer, J.R., Lee, J.S., Ciuleanu, T.E., Bernabe Caro, R., et al. (2023) Five-Year Survival Outcomes with Nivolumab Plus Ipilimumab versus Chemotherapy as First-Line Treat-ment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227. Journal of Clinical Oncology, 41, 1200-1212. https://doi.org/10.1200/JCO.22.01503 |
| [11] | Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. https://doi.org/10.3322/caac.21660 |
| [12] | Cao, W., Chen, H.D., Yu, Y.W., et al. (2021) Changing Profiles of Cancer Burden Worldwide and in China: A Secondary Analysis of the Global Cancer Statistics 2020. Chinese Medical Journal (England), 134, 783-791.
https://doi.org/10.1097/CM9.0000000000001474 |
| [13] | Chen, P., Liu, Y., Wen, Y. and Zhou, C. (2022) Non-Small Cell Lung Cancer in China. Cancer Communications (London), 42, 937-970. https://doi.org/10.1002/cac2.12359 |
| [14] | Schreiber, R.D., Old, L.J. and Smyth, M.J. (2011) Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion. Science, 331, 1565-1570. https://doi.org/10.1126/science.1203486 |
| [15] | Chen, D.S. and Mellman, I. (2013) Oncology Meets Immunology: The Cancer-Immunity Cycle. Immunity, 39, 1-10.
https://doi.org/10.1016/j.immuni.2013.07.012 |
| [16] | Socinski, M.A., Jotte, R.M., Cappuzzo, F., Nishio, M., et al. (2023) Association of Immune-Related Adverse Events with Efficacy of Atezolizumab in Patients with Non-Small Cell Lung Cancer: Pooled Analyses of the Phase 3 IMpower130, IMpower132, and IMpower150 Randomized Clinical Trials. JAMA Oncology, 9, 527-535.
https://doi.org/10.1001/jamaoncol.2022.7711 |
| [17] | Zhou, F., Qiao, M. and Zhou, C. (2021) The Cutting-Edge Pro-gress of Immune-Checkpoint Blockade in Lung Cancer. Cellular & Molecular Immunology, 18, 279-293. https://doi.org/10.1038/s41423-020-00577-5 |
| [18] | Kennedy, L.B. and Salama, A. (2020) A Review of Cancer Im-munotherapy Toxicity. CA: A Cancer Journal for Clinicians, 70, 86-104. https://doi.org/10.3322/caac.21596 |
| [19] | Ai, L., Xu, A. and Xu, J. (2020) Roles of PD-1/PD-L1 Pathway: Signal-ing, Cancer, and beyond. Advances in Experimental Medicine and Biology, 1248, 33-59. https://doi.org/10.1007/978-981-15-3266-5_3 |
| [20] | Han, Y., Liu, D. and Li, L. (2020) PD-1/PD-L1 Pathway: Cur-rent Researches in Cancer. American Journal of Cancer Research, 10, 727-742. |
| [21] | Hosseini, A., Gharibi, T., Marofi, F., et al. (2020) CTLA-4: From Mechanism to Autoimmune Therapy. International Immunopharmacology, 80, Article ID: 106221. https://doi.org/10.1016/j.intimp.2020.106221 |
| [22] | 李浩洋, 王敬慧. 晚期非小细胞肺癌免疫治疗进展[J]. 中国肺癌杂志, 2021, 24(2): 131-140. |
| [23] | Patel, S.A. and Weiss, J. (2020) Advances in the Treatment of Non-Small Cell Lung Cancer: Immunotherapy. Clinics in Chest Medicine, 41, 237-247. https://doi.org/10.1016/j.ccm.2020.02.010 |
| [24] | Vansteenkiste, J., Wauters, E., Reymen, B., et al. (2019) Current Status of Immune Checkpoint Inhibition in Early-Stage NSCLC. Annals of Oncology, 30, 1244-1253. https://doi.org/10.1093/annonc/mdz175 |
| [25] | Vaidya, P. and Cohen, E.E.W. (2019) Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes. Clinical Cancer Research, 25, 4592-4602. https://doi.org/10.1158/1078-0432.CCR-18-1538 |
| [26] | Garon, E.B., Rizvi, N.A., Hui, R., et al. (2015) Pembroli-zumab for the Treatment of Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 372, 2018-2028. https://doi.org/10.1056/NEJMoa1501824 |
| [27] | Herbst, R.S., Baas, P., Kim, D.W., Felip, E., et al. (2016) Pem-brolizumab versus Docetaxel for Previously Treated, PD-L1-Positive, Advanced Non-Small-Cell Lung Cancer (KEYNOTE-010): A Randomised Controlled Trial. The Lancet, 387, 1540-1550. https://doi.org/10.1016/S0140-6736(15)01281-7 |
| [28] | Reck, M., Rodríguez-Abreu, D., Robinson, A.G., et al. (2016) Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 375, 1823-1833.
https://doi.org/10.1056/NEJMoa1606774 |
| [29] | Reck, M., Rodríguez-Abreu, D., Robinson, A.G., et al. (2019) Up-dated Analysis of KEYNOTE-024: Pembrolizumab versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer with PD-L1 Tumor Proportion Score of 50% or Greater. Journal of Clinical Oncology, 37, 537-546. https://doi.org/10.1200/JCO.18.00149 |
| [30] | Mok, T.S.K., Wu, Y.L., Kudaba, I., Kowalski, D.M., et al. (2019) Pembrolizumab versus Chemotherapy for Previously Untreated, PD-L1-Expressing, Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (KEYNOTE-042): A Randomised, Open-Label, Controlled, Phase 3 Trial. The Lancet, 393, 1819-1830.
https://doi.org/10.1016/S0140-6736(18)32409-7 |
| [31] | Brahmer, J., Reckamp, K.L., Baas, P., et al. (2015) Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 373, 123-135.
https://doi.org/10.1056/NEJMoa1504627 |
| [32] | Larkin, J., Chiarion-Sileni, V., Gonzalez, R., et al. (2015) Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. The New England Journal of Medicine, 373, 23-34. https://doi.org/10.1056/NEJMoa1504030 |
| [33] | Nghiem, P.T., Bhatia, S., Lipson, E.J., et al. (2016) PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. The New England Journal of Medicine, 374, 2542-2552. https://doi.org/10.1056/NEJMoa1603702 |
| [34] | Powles, T., O’Donnell, P.H., Massard, C., et al. (2017) Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results from a Phase 1/2 Open-Label Study. JAMA Oncology, 3, e172411.
https://doi.org/10.1001/jamaoncol.2017.2411 |
| [35] | Fehrenbacher, L., Spira, A., Ballinger, M., et al. (2016) Atezoli-zumab versus Docetaxel for Patients with Previously Treated Non-Small-Cell Lung Cancer (POPLAR): A Multicentre, Open-Label, Phase 2 Randomised Controlled Trial. The Lancet, 387, 1837-1846. https://doi.org/10.1016/S0140-6736(16)00587-0 |
| [36] | Weinstock, C., Khozin, S., Suzman, D., et al. (2017) U.S. Food and Drug Administration Approval Summary: Atezolizumab for Metastatic Non-Small Cell Lung Cancer. Clinical Cancer Research, 23, 4534-4539.
https://doi.org/10.1158/1078-0432.CCR-17-0540 |
| [37] | Weinmann, S.C. and Pisetsky, D.S. (2019) Mechanisms of Immune-Related Adverse Events during the Treatment of Cancer with Immune Checkpoint Inhibitors. Rheumatology (Oxford), 58, vii59-vii67.
https://doi.org/10.1093/rheumatology/kez308 |
| [38] | Xu, C., Chen, Y.P., Du, X.J., et al. (2018) Comparative Safety of Immune Checkpoint Inhibitors in Cancer: Systematic Review and Network Meta-Analysis. BMJ, 363, k4226. https://doi.org/10.1136/bmj.k4226 |
| [39] | Abdel-Wahab, N., Shah, M., Lopez-Olivo, M.A., et al. (2018) Use of Im-mune Checkpoint Inhibitors in the Treatment of Patients with Cancer and Preexisting Autoimmune Disease: A Systematic Review. Annals of Internal Medicine, 168, 121-130. https://doi.org/10.7326/M17-2073 |
| [40] | Ramos-Casals, M., Brahmer, J.R., Callahan, M.K., et al. (2020) Immune-Related Adverse Events of Checkpoint Inhibitors. Nature Reviews Disease Primers, 6, Article No. 38. https://doi.org/10.1038/s41572-020-0160-6 |
| [41] | John, T., Sakai, H., Ikeda, S., Cheng, Y., et al. (2022) First-Line Nivolumab plus Ipilimumab Combined with Two Cycles of Chemotherapy in Ad-vanced Non-Small Cell Lung Cancer: A Subanalysis of Asian Patients in CheckMate 9LA. International Journal of Clinical Oncology, 27, 695-706. https://doi.org/10.1007/s10147-022-02120-0 |
| [42] | Tang, Q., Chen, Y., Li, X., Long, S., et al. (2022) The Role of PD-1/PD-L1 and Application of Immune-Checkpoint Inhibitors in Human Cancers. Frontiers in Immunology, 13, Article ID: 964442.
https://doi.org/10.3389/fimmu.2022.964442 |
| [43] | Planchard, D., Popat, S., Kerr, K., et al. (2018) Metastatic Non-Small Cell Lung Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Annals of Oncology, 29, iv192-iv237.
https://doi.org/10.1093/annonc/mdy275 |
| [44] | Zhang, Y.X., Zhou, H.Q. and Zhang, L. (2018) Which Is the Optimal Immunotherapy for Advanced Squamous Non-Small-Cell Lung Cancer in Combination with Chemotherapy: Anti-PD-1 or Anti-PD-L1? The Journal for ImmunoTherapy of Cancer, 6, 135. https://doi.org/10.1186/s40425-018-0427-6 |
| [45] | Cascone, T., William, W.N., Weissferdt, A., et al. (2021) Neoad-juvant Nivolumab or Nivolumab plus Ipilimumab in Operable Non-Small Cell Lung Cancer: The Phase 2 Randomized NEOSTAR Trial. Nature Medicine, 27, 504-514.
https://doi.org/10.1038/s41591-020-01224-2 |
